About Naronapride (ATI-7505)
Oral tablet formulation
Renexxion has adopted a pipeline-in-a-pill strategy: naronapride has successfully completed several Phase-2 clinical trials for the treatment of multiple gastrointestinal disorders including gastroparesis, chronic idiopathic constipation (CIC), gastro-esophageal reflux disease (GERD), and erosive esophagitis (EE). The FDA DGIEP now has agreed formally to a rapid and low-risk pathway to approval in chronic idiopathic constipation (CIC) that does not require extensive cardiovascular safety testing.
Naronapride is being developed in the US for PPI non-responsive symptomatic GERD (PPI-nrsGERD) and gastroparesis and is currently in Phase 2b trials in Europe for gastroparesis, with our partner Dr. Falk Pharma GmbH.
Renexxion has adopted a pipeline-in-a-pill strategy: naronapride has successfully completed several Phase-2 clinical trials for the treatment of multiple gastrointestinal disorders including gastroparesis, chronic idiopathic constipation (CIC), gastro-esophageal reflux disease (GERD), and erosive esophagitis (EE). The FDA DGIEP now has agreed formally to a rapid and low-risk pathway to approval in chronic idiopathic constipation (CIC) that does not require extensive cardiovascular safety testing.
Naronapride is being developed in the US for PPI non-responsive symptomatic GERD (PPI-nrsGERD) and gastroparesis and is currently in Phase 2b trials in Europe for gastroparesis, with our partner Dr. Falk Pharma GmbH.